Alkermes (ALKS) Return on Invested Capital (2011 - 2025)
Alkermes' (ALKS) quarterly Return on Invested Capital came in at 0.85% in Q2 2025, up 55.0% year-on-year from 0.55% in Q2 2024, and up 61.18% on a QoQ basis from 0.53% in Q1 2025.
Alkermes (ALKS) Return on Invested Capital (2011 - 2025) Analysis & Trends
Alkermes (ALKS) has 15 years of Return on Invested Capital data on file, last reported at 0.85% in Q2 2025.
- On a quarterly basis, Return on Invested Capital rose 55.0% year-over-year to 0.85% in Q2 2025; TTM through Jun 2025 was 0.85%, a 55.0% increase from a year earlier, with the FY2023 full-year figure at 1.7%, up 173.0% from the prior year.
- Return on Invested Capital for Q2 2025 stood at 0.85%, up from 0.53% in the prior quarter.
- Over the last five years, Return on Invested Capital for ALKS reached as high as 0.85% in Q2 2025 and fell as low as 0.08% in Q1 2021.
- Historically, Return on Invested Capital has averaged 0.22% across 5 years, with a median of 0.17% in 2023.
- Across the five-year window, Return on Invested Capital fell 15 bps in 2023 and jumped 55 bps in 2025, its largest moves.
- Year by year, Return on Invested Capital stood at 0.08% in 2021, then plunged by 108 bps to 0.01% in 2022, then soared by 6265 bps to 0.43% in 2023, then declined by 6 bps to 0.4% in 2024, then soared by 112 bps to 0.85% in 2025.
- Per Business Quant data, the three most recent Return on Invested Capital figures were 0.85% in Q2 2025, 0.53% in Q1 2025, and 0.4% in Q4 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.01% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.01% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.00% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.00% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.03% |
| 10 | Alkermes | 9.72 Bn | 9.21 Bn | 331.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 0.85% |
| Mar 31, 2025 | 0.53% |
| Dec 31, 2024 | 0.40% |
| Sep 30, 2024 | 0.30% |
| Jun 30, 2024 | 0.30% |
| Mar 31, 2024 | 0.46% |
| Dec 31, 2023 | 0.43% |
| Sep 30, 2023 | 0.37% |
| Jun 30, 2023 | 0.25% |
| Mar 31, 2023 | -0.06% |
| Dec 31, 2022 | -0.01% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.08% |
| Mar 31, 2022 | 0.09% |
| Dec 31, 2021 | 0.08% |
| Sep 30, 2021 | -0.05% |
| Jun 30, 2021 | -0.04% |
| Mar 31, 2021 | -0.08% |
| Dec 31, 2020 | -0.10% |
| Sep 30, 2020 | -0.09% |